Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
Cullinan Therapeutics reported initial Phase 1 clinical data for CLN-978, a CD19xCD3 T cell engager, showing clinical benefit including remissions in patients with refractory systemic lupus erythematosus (SLE) and difficult-to-treat rheumatoid arthritis (RA). Data demonstrated deep, dose-dependent B cell depletion in blood and tissue along with a f…